• news
    • Press releases
    • Blog
    • Media Coverage
    • Event
  • Documents
  • About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • knowledgehub
    • what is KI EIS fund?
  • Contact

o2h-ventures

  • news
    • Press releases
    • Blog
    • Media Coverage
    • Event
  • Documents
  • About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • knowledgehub
    • what is KI EIS fund?
  • Contact

Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more

o2h Ventures ‘Knowledge Intensive Human Health EIS Fund’ invests into BiVictriX Therapeutics
o2h Ventures ‘Knowledge Intensive Human Health EIS Fund’ invests into BiVictriX Therapeutics
Aug 5 2021

Cambridge, UK, 05 August 2021: o2h Ventures is delighted to announce an investment into BiVictriX Therapeutics, an emerging biotechnology company applying a novel approach to develop next-generation cancer therapies using insights derived from frontline clinical experience. 

BiVictriX is dedicated to applying a novel approach in developing safer and effective cancer therapies, by revolutionizing cancer therapy and making curative treatments available to all; By delivering a broad pipeline of proprietary, first-in-class Bi-Cygni® therapeutics to enable potentially higher dosing and more aggressive tumor eradication in patients, without causing harmful side effects.

The company also announced that it will be listed on the AIM market of the London Stock Exchange, raising £7.5m million from its initial public offering (IPO). With BiVictriX’s listing on AIM, 33-year-old CEO Tiffany Thorn becomes one of the youngest female CEOs of a UK-based publicly listed technology firm.

o2h Ventures (FRN 812245) is part of the o2h Group that has built an ecosystem to collaborate with early-stage businesses.  o2h Ventures was launched in 2018 to provide pre-seed and seed capital to companies in the biotech therapeutics space based in the UK.  To date the fund and pre-fund have invested into over 35 companies, several of which have now raised significant funds from overseas, listed and built game-changing drugs to benefit human health.

Sunil Shah, CEO of o2h Ventures, said: “We are very excited to invest in BiVictriX as their lead program looks to Target Acute Myeloid Leukemia, one of the most virulent and fast-growing cancers with horrific survival rates.  Their platform could not only provide highly specific drugs for AML but could also be applied to other cancer indications if successful. “

Tiffany Thorn, CEO and Founder of BiVictriX, said: “We are delighted that o2h Ventures were able to form part of the syndicate, they are a fund focused on drug discovery therapeutics and will be able to provide us with strong connections and advice as we scale our platform”.

About o2h Ventures:

The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years.  o2h Ventures operates from their proprietary 2.7 acre Mill SciTech Park where they are developing a unique model for incubating small life science companies.

For more information, please visit www.o2hventures.com 

About the o2h human health knowledge-intensive EIS fund:

The o2h human health EIS fund is the first HMRC-approved knowledge-intensive fund in the UK. The fund focuses on investing in EIS companies covering novel drug discovery & AI, digital therapeutics, and enabling services.

To support the Government’s aim to strengthen and grow UK innovation, which was known to be capital and research-intensive, the EIS knowledge-intensive fund has been launched to pledge support to companies working in this space, providing them access to capital to develop their early novel ideas.

For more information, please visit https://o2hventures.com/funds/the-o2h-human-health-ki-eis-fund

About BiVictriX Therapeutics:

Derived from frontline clinical experience, BiVictriX is a rapidly emerging biotechnology company applying a novel approach to develop safer, more effective cancer therapies. The Company, which was recently listed on the AIM of the London Stock Exchange (AIM: BVX), is pioneering a novel approach to cancer treatment based on its proprietary Bi-Cygni® therapeutics, potentially higher dosing and more aggressive tumor eradication without causing harmful side-effects to patients.

BiVictriX’s access to state-of-the-art techniques identifies combinations of cancer-specific targets for both solid and liquid tumors. The Company’s lead candidate is BVX001, designed to bring a genuinely novel immunotherapeutic approach to patients with acute myeloid leukemia (AML). 

BiVictriX is headquartered in Macclesfield, UK, with additional specialized laboratory facilities in St Asaph, Wales.

For more information, visit- www.bivictrix.com.

For further information, please contact:
o2h Ventures Ltd

Ajit Singh

Email: ajit@o2h.com

BiVictriX Therapeutics

Tiffany Thorn, Founder & CEO

Email: tiffany.thorn@bivictrix.com 

 

Connect with us
  • linkedin
  • youtube
  • email
o2h-ventures
recent press releases
  • o2h-ventures o2h Ventures makes an SEIS Investment into Five Alarm Bio to strengthen anti-ageing science 28 Feb 2023
  • o2h-ventures Exciting news as o2h Ventures’ portfolio company Small Pharma, unveils positive top-line results of their Phase IIa clinical trial for treating MDD 31 Jan 2023
  • o2h-ventures o2h Ventures backed Kuano wins Innovate UK funding for designing the next generation of cancer drugs 18 Jan 2023
o2h-ventures
o2h Ventures Limited
Hauxton House,
The Mill SciTech Park,
Mill Lane, Hauxton
Cambridge
CB22 5HX
07341612481
invest@o2h.com
about
  • about us
  • team
  • portfolio
  • funds
insights and news
  • knowledge hub
  • press releases
  • blog
  • event
  • documents
connect with us
  • linkedin
  • youtube
  • email
Please refer to the relevant fund’s full risk warnings contained in their Information Memorandums.
Your capital is at risk. Investing in early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. o2h Ventures’ funds are targeted exclusively at sophisticated or high net worth investors who understand these risks and make their own investment decisions. Tax relief depends on an individual’s circumstances and may change in the future. In addition, the availability of tax relief depends on the company invested in maintaining its qualifying status. Past performance is not a reliable indicator of future performance. You should not rely on any past performance as a guarantee of future investment performance.
o2h ventures Limited is regulated and authorised by the Financial Conduct Authority (FRN 812245). Capital at risk, only suitable for high net worth and sophisticated investors
© 2025 o2h ventures
  • Privacy Policy
  • Blog
  • Contact us

Risk Information

Due to the potential for losses, the Financial Conduct Authority (FCA) considers this investment to be high risk

What are the key risks?

1 – You could lose all the money you invest

• If the business you invest in fails, you are likely to lose 100% of the money you invest. Most start-up businesses fail.

2 – You are unlikely to be protected if something goes wrong

• Protection from the Financial Services Compensation Scheme (FSCS), in relation to claims against failed regulated firms, does not cover poor investment performance. Try the FSCS investment protection checker here. (https://www.fscs.org.uk/check/investment-protection-checker)

• Protection from the Financial Ombudsman Service (FOS) does not cover poor investment performance. If you have a complaint against an FCA-regulated firm, FOS may be able to consider it. Learn more about FOS protection here. (https://www.financial-ombudsman.org.uk/consumers)

3 – You won’t get your money back quickly

• Even if the business you invest in is successful, it may take several years to get your money back. You are unlikely to be able to sell your investment early.

• The most likely way to get your money back is if the business is bought by another business or lists its shares on an exchange such as the London Stock Exchange. These events are not common.

• If you are investing in a start-up business, you should not expect to get your money back through dividends. Start-up businesses rarely pay these.

4 – Don’t put all your eggs in one basket

• Putting all your money into a single business or type of investment for example, is risky. Spreading your money across different investments makes you less dependent on any one to do well.

• A good rule of thumb is not to invest more than 10% of your money in high-risk investments (https://www.fca.org.uk/investsmart/5-questions-ask-you-invest)

5 – The value of your investment can be reduced

• The percentage of the business that you own will decrease if the business issues more shares. This could mean that the value of your investment reduces, depending on how much the business grows. Most start-up businesses issue multiple rounds of shares.

• These new shares could have addition rights that your shares don’t have, such as the right to receive a fixed dividend, which could further reduce your chances of getting a return on your investment.

If you are interested in learning more about how to protect yourself, visit the FCA’s website here (https://www.fca.org.uk/investsmart)